Easywell Biomedicals, Inc. Stocks

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; TLX-011 for treatment of inflammatory lesions of rosacea; TLX-015 a prevention and treatment medicine for postpartum hemorrhage; TLX-018, a hemorrhage treatment drug; TLX-030, an anti-inflammatory medicine; TLX-47, an anti-inflammatory drug; and TLX-024, an anticonvulsant. It also develops TWB-201 for Parkinson patch; TLX-501, a urinary medicine; and TLX-502, a pneumonia medicine. In addition, the company provides thermometers, medical devices, and health food and products. It has a collaborative development agreement with Handa Pharmaceuticals and Handa Neuroscience, LLC for the development of TLX-050 for the treatment of neurological disorders. The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.